Turkish antitrust regulators opened a formal investigation into Teva Pharmaceutical in early August 2026, and the announcement, published on the Turkish Competition Board's website, contains an allegation with an unusual shape. The world's largest generic drugmaker, the board says, may have manipulated the patent system and created misleading impressions about rival medicines before health care authorities, all to make it harder for competing products to reach the market.
Nothing has been proven. The investigation is an opening, not a verdict, and Teva has denied wrongdoing and pointed to a pending appeal of a related European case. But the shape of the allegation is worth pausing on, because the conduct described is the exact conduct that the generics industry, with Teva as its largest member, exists to dismantle. The company that built its business attacking pharmaceutical moats stands accused, in Ankara and previously in Brussels, of digging the same moat around one product of its own.
The probe names the branded playbook
The Turkish Competition Board disclosed its decision on August 21, after opening the investigation on August 6 under Article 6 of the country's competition law, which prohibits abuse of a dominant position. The probe covers the economic unity of Teva's Turkish subsidiary, its European arm, and the parent company. Two lines of alleged conduct are at issue. The first is a form of patent system manipulation: the strategic use of divisional patent applications covering manufacturing processes and dosage regimens, filed after the basic molecule patent expired, along with patent withdrawal practices, in a way that may have made it harder for competitors to enter the market. The second is disparagement: creating a misleading impression before health care authorities about the efficacy and safety of competing products.
The regulator did not name a specific drug. Industry coverage has connected the probe to Copaxone, Teva's long-running multiple sclerosis franchise, and the connection matters less for the specific medicine than for the pattern. These are not obscure accusations. They are the standard branded-company tactics that generic manufacturers have spent three decades fighting in courts and parliaments: thickets of secondary patents around an expiring blockbuster, and campaigns that cast doubt on the therapeutic equivalence of cheaper rivals. The generic industry's founding argument is that both practices harm patients and public budgets by delaying competition. The accusation now facing the industry's biggest company is that it used both.
Brussels has already walked this ground
The Turkish probe does not arrive in a vacuum. In October 2024, the European Commission fined Teva 462.6 million euros, about $503 million, for conduct it described in nearly identical terms. The Commission found that as Copaxone's basic patent neared expiry in 2015, Teva filed a staggered series of divisional patents around the drug's manufacturing process and dosing regimen, enforced them to win interim injunctions against rivals, and then withdrew the applications whenever they looked likely to be revoked, avoiding formal invalidity rulings that would have weakened the remaining patents. The result, the Commission concluded, was to force competitors into repeated, near-identical litigation and delay their entry for up to nine years, from 2015 to 2024.
The second strand of the European case was a systematic disparagement campaign against a rival glatiramer acetate product made by Synthon. The Commission found that Teva spread information contradicted by health authorities' own findings, casting doubt on the rival's safety, efficacy, and therapeutic equivalence among doctors, insurers, and national pricing bodies across seven member states. Competition Commissioner Margrethe Vestager said at the time that Teva had "gamed" the patent system. Rival versions of the drug, the Commission noted, could have been up to 80 percent cheaper than Copaxone.
Teva strongly disputes the decision. The company called the Commission's legal theories extreme, untested, and factually unsupported, and it is appealing before the European Court, a process that can take years. All of the divisional patents at issue have since been annulled. And this was not the company's first European antitrust encounter: in 2020, regulators fined Teva and Cephalon for colluding to delay a cheaper generic sleep-disorder drug, a fine Teva is also appealing. For the record's sake, the Turkish board's announcement came with the company's shares up 1.5 percent on the day, at $37.48. The market has priced this story before.
It helps to understand what the company was defending. Copaxone was once among the best-selling medicines in the world, a franchise that generated billions a year at its peak and carried Teva's profitability for more than two decades. A product like that is not replaced easily, and a company watching its largest asset decline faces the strongest commercial incentive that exists in pharmaceuticals: extend the asset's life by any lawful means, and some regulators say by more than lawful means. Both investigations are, at bottom, questions about where that incentive met the company's other identity.
One company, two business models, one seam
The reason the allegations land strangely is that they sit exactly on the seam between the two companies that Teva is. One Teva is the generic champion: a firm whose entire economic identity is challenging patents, proving interchangeability, and persuading doctors and payers that a cheaper copy is the same medicine. The other Teva is a branded manufacturer with blockbusters of its own to defend, of which Copaxone, a drug that once generated billions a year, is the emblem. Every branded franchise in decline faces the same temptation that the generic side of the house exists to attack: extend the patent life, and undermine the copy.
The alleged conduct is the point where the two halves of the business meet, and where they are least compatible. The same disparagement argument that a generic firm makes in reverse, that a rival's copy is not truly equivalent, is legitimate marketing when the product being questioned is a competitor's copy. It becomes an abuse of dominance, in the European theory, when the speaker is the dominant supplier using its position to keep the copy off the market. Patent challenges are sacred to the generics industry. Patent thickets are its enemy. The Turkish board's allegation, like the Commission's before it, is essentially that Teva used the second company's tools to protect the first company's franchise.
This is not a criticism of any individual. It is a description of a structural conflict built into the industry's largest player. Companies that wear both hats make both arguments, in different courtrooms, on different days, and the line between legitimate defense and exclusionary conduct is drawn case by case by regulators. The European Commission has now drawn the line in one place. Turkey is considering whether to draw it in another. Nothing in either case has been decided against the company in a final court, and Teva's right to appeal is part of the process, not a footnote to it.
What Turkey adds to the pattern
The Turkish probe extends a map that is still being drawn. The Commission's Copaxone decision was the first European fine for disparagement as an abuse of dominance and the first for abusive patent game-playing. A similar disparagement investigation into Vifor Pharma was settled with commitments in 2024, without a fine. Turkey's board has been increasingly active against global drugmakers, and its probe covers the same two conduct theories in one investigation. If the pattern holds, the next several years will produce guidance on where the seam sits: on what grounds a company may defend its franchise, and on what grounds the defense becomes the offense.
For patients and payers, the stakes are the ones the generics industry has always articulated. Every year a cheaper equivalent is delayed is a year of higher prices paid by someone, usually public health systems. The Commission estimated the Copaxone delay cost health budgets across seven countries. Turkish authorities will now examine whether something similar happened inside their own borders, and they will do it with the benefit of a European record that has already named the conduct, quantified it, and tested the company's defenses against it.
The Turkish process will not move quickly. The board's investigations typically run through document requests, possible dawn raids, written defenses, and a decision that can be appealed, and the pipeline often takes years. Any penalty would be calculated as a share of turnover, accompanied by behavioral remedies rather than a single check, which means the real remedy under consideration is not money but conduct: how Teva files patents in Turkey, and what it tells Turkish health authorities about its competitors' products. That is the part of the case that could matter long after any fine is spent.
The investigation will run for years, through document requests, written defenses, and appeals, and it may end in a fine, in behavioral remedies, or in nothing at all. The allegations are unproven and denied. But whatever the outcome, the case has already done one useful thing. It has made the tension inside the world's largest generic drugmaker impossible to ignore: the same firm that has spent its life arguing that drugs should be cheaper and patents should be pierced now faces the accusation that, for one of its own drugs, it argued the opposite.
Primary sources
- The Turkish Competition Board's announcement for the probe's opening date, the Article 6 basis, the entities covered, and the two theories of alleged conduct.
- STAT's Pharmalot report by Ed Silverman for the disclosure date, Teva's response, the parallel with the European case, and the share price detail.
- The European Commission's Copaxone decision, as analyzed in the Herbert Smith Freehills Kramer note and the Paul Weiss client memo, for the fine amount, the divisional patent mechanics, the Synthon campaign, the Vestager statement, Teva's appeal, and the 2020 Cephalon case, with Citeline's coverage connecting the Turkish probe to Copaxone divisionals.